Darren Rowles - Sona Nanotech Pres Officer

All Insiders . USA . 
Stock . Sona Nanotech . Stakeholders . Insider . Darren Rowles
SNANF Stock  USD 0.19  0.01  5.00%   

Insider

Darren Rowles is Pres Officer of Sona Nanotech
Age 43
Phone902-442-0653
Webhttps://www.sonanano.com

Sona Nanotech Management Efficiency

The company has return on total asset (ROA) of (2.3852) % which means that it has lost $2.3852 on every $100 spent on assets. This is way below average. Sona Nanotech's management efficiency ratios could be used to measure how well Sona Nanotech manages its routine affairs as well as how well it operates its assets and liabilities.
Sona Nanotech has accumulated 700.76 K in total debt with debt to equity ratio (D/E) of 2.91, implying the company greatly relies on financing operations through barrowing. Sona Nanotech has a current ratio of 1.03, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sona Nanotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sona Nanotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sona Nanotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sona to invest in growth at high rates of return. When we think about Sona Nanotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Stephen MSNeuronetics
60
Vikram JogStandard Biotools
68
Matt StaufferBiodesix
N/A
Ryan SiurekBiodesix
52
Hannah BibleStar Equity Holdings
43
Debra ZackExagen Inc
65
Zvi DavidDarioHealth Corp
63
Shaokun ChuaiBurning Rock Biotech
45
Dr IIIBiodesix
53
Martin ShirleyStar Equity Holdings
61
Heinrich RderBiodesix
N/A
Carl BScGenetic Technologies
69
David NobleStar Equity Holdings
54
Simon MorrissGenetic Technologies
51
Steven GravesSera Prognostics
N/A
MingChou LeeExagen Inc
N/A
Jeffrey EberweinStar Equity Holdings
53
Kevin CamilleriGenetic Technologies
47
Andrew QuongStandard Biotools
N/A
Paul KearneySera Prognostics
56
Robert CawthornBiodesix
87
Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. Sona Nanotech operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. Sona Nanotech [SNANF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Asset-2.39

Sona Nanotech Leadership Team

Elected by the shareholders, the Sona Nanotech's board of directors comprises two types of representatives: Sona Nanotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sona. The board's role is to monitor Sona Nanotech's management team and ensure that shareholders' interests are well served. Sona Nanotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sona Nanotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Regan, Chief Officer
Darren Rowles, Pres Officer
Robert Randall, CFO Sec
Gerrard Marangoni, CoFounder Board
Kulbir Singh, CoFounder RD
Mike McAlduff, Director Founder

Sona Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Sona Nanotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-2.39
Current Valuation5.72 M
Shares Outstanding68.99 M
Shares Owned By Insiders13.60 %
Price To Book21.86 X
EBITDA(10.28 M)
Net Income(10.37 M)
Cash And Equivalents402.77 K
Cash Per Share0.01 X
Total Debt700.76 K

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in Sona OTC Stock

Sona Nanotech financial ratios help investors to determine whether Sona OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sona with respect to the benefits of owning Sona Nanotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY